Global Patent Index - EP 1461068 A4

EP 1461068 A4 20060329 - METHODS OF COMPOSITIONS FOR NORMALIZING LIPID LEVELS IN MAMMALIAN TISSUES

Title (en)

METHODS OF COMPOSITIONS FOR NORMALIZING LIPID LEVELS IN MAMMALIAN TISSUES

Title (de)

VERFAHREN UND ZUSAMMENSETZUNGEN ZUR NORMALISIERUNG DER LIPIDSPIEGEL IN SÄUGERGEWEBEN

Title (fr)

PROCEDES ET COMPOSITIONS POUR NORMALISER LES NIVEAUX LIPIDIQUES DANS LES TISSUS MAMMALIENS

Publication

EP 1461068 A4 20060329 (EN)

Application

EP 02803945 A 20021126

Priority

  • NZ 0200262 W 20021126
  • NZ 51573101 A 20011126
  • US 33342201 P 20011126

Abstract (en)

[origin: WO03045424A1] The invention provides methods of stimulating lipolysis in a mammalian cells and tissues by contacting the cell or tissue with an agonist of a CGRP receptor such as the high affinity CGRP receptor. The agonist may preferentially stimulate the high affinity CGRP receptor compared to the metabolic amylin receptor. Methods for screening for identifying receptor agonists are provided, pharmaceutical compositions comprising such agonists, and therapeutic regimens using such agonists are provided.

IPC 1-7

A61K 38/23; A61P 3/06; A61P 3/04; A61P 9/12; A61P 5/06

IPC 8 full level

G01N 33/50 (2006.01); A61K 38/22 (2006.01); A61K 38/23 (2006.01); A61P 3/04 (2006.01); A61P 3/06 (2006.01); A61P 3/10 (2006.01); A61P 5/06 (2006.01); A61P 5/50 (2006.01); A61P 9/12 (2006.01); A61P 43/00 (2006.01); G01N 33/15 (2006.01); G01N 33/92 (2006.01)

CPC (source: EP)

A61K 38/225 (2013.01); A61P 3/04 (2017.12); A61P 3/06 (2017.12); A61P 3/10 (2017.12); A61P 5/06 (2017.12); A61P 5/50 (2017.12); A61P 9/12 (2017.12); A61P 43/00 (2017.12); G01N 33/92 (2013.01); G01N 2500/00 (2013.01); G01N 2800/044 (2013.01)

Citation (search report)

  • [X] WO 9604928 A1 19960222 - HUMAN GENOME SCIENCES INC [US], et al
  • [X] EP 0845269 A2 19980603 - WO WEIHAN [AT]
  • [X] EP 0309100 A2 19890329 - AMYLIN CORP [US]
  • [X] CHATZIPANTELI K ET AL: "CALCITONIN GENE-RELATED PEPTIDE IS AN ADIPOSE-TISSUE NEUROPEPTIDE WITH LIPOLYTIC ACTIONS", ENDOCRINOLOGY AND METABOLISM, LONDON, GB, vol. 3, no. 4, 1996, pages 235 - 242, XP008057490, ISSN: 1074-939X
  • [X] MOORE MARY COURTNEY ET AL: "Insulin- and glucagon-independent effects of calcitonin gene-related peptide in the conscious dog", METABOLISM CLINICAL AND EXPERIMENTAL, vol. 48, no. 5, May 1999 (1999-05-01), pages 603 - 610, XP002362125, ISSN: 0026-0495
  • [X] HETTIARACHCHI M ET AL: "Rat amylin-(8-37) enhances insulin action and alters lipid metabolism in normal and insulin-resistant rats", AMERICAN JOURNAL OF PHYSIOLOGY, vol. 273, no. 5 PART 1, November 1997 (1997-11-01), pages E859 - E867, XP002362126, ISSN: 0002-9513
  • [X] YE J-M ET AL: "EVIDENCE THAT AMYLIN STIMULATES LIPOLYSIS IN VIVO: A POSSIBLE MEDIATOR OF INDUCED INSULIN RESISTANCE", AMERICAN JOURNAL OF PHYSIOLOGY, AMERICAN PHYSIOLOGICAL SOCIETY, BETHESDA, MD, US, vol. 280, no. 4, PART 1, April 2001 (2001-04-01), pages E562 - E569, XP009009879, ISSN: 0002-9513
  • See references of WO 03045424A1

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

DOCDB simple family (publication)

WO 03045424 A1 20030605; AU 2002356469 A1 20030610; AU 2002356469 A2 20030610; AU 2009201147 A1 20090423; CA 2471833 A1 20030605; CN 1617737 A 20050518; EP 1461068 A1 20040929; EP 1461068 A4 20060329; JP 2005523418 A 20050804

DOCDB simple family (application)

NZ 0200262 W 20021126; AU 2002356469 A 20021126; AU 2009201147 A 20090326; CA 2471833 A 20021126; CN 02827569 A 20021126; EP 02803945 A 20021126; JP 2003546925 A 20021126